Bryce Chackerian, PhD


Dr. Chackerian grew up in Northern California, received his BA at the University of California, Berkeley, and his PhD studying the immune selection of Simian Immunodeficiency Virus with Julie Overbaugh at the University of Washington.

He then trained in John Schiller's laboratory at the National Cancer Institute. In 2004 he joined the Department of Molecular Genetics and Microbiology at the University of New Mexico. He is a member of the UNM Cancer Center and the Center for Infectious Disease and Immunity.

Key Publications

*Current/Former trainees.

Lucie Jelínková*, Hugo Jhun, Allison Eaton, Nikolai Petrovsky, Fidel Zavala, & Bryce Chackerian (2020)An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite ProteinbioRxiv 2020.08.07.241802

Joyner JA, Daly SM, Peabody J, Triplett KD, Pokhrel S, Elmore BO, Adebanjo D, Peabody DS, Chackerian B, & PR Hall (2020)Vaccination with VLPs Presenting a Linear Neutralizing Domain of S. aureus Hla Elicits Protective ImmunityToxins. 2020;12(7):450. Published 2020 Jul 11. doi:10.3390/toxins12070450

Bryce Chackerian and David S. Peabody (2020). Factors that Govern the induction of long-lived Plasma Cells. Viruses. 12, 74; doi:10.3390/v12010074.

Chen, Z., Wholey, W., Najafabadi, A.H., Moon, J.J., Grigorova, I., Chackerian, B., and W. Cheng (2020). Self-Antigens Displayed on Liposomal Nanoparticles above a Threshold of Epitope Density Elicit Class-switched Autoreactive Antibodies Independent of T-cell HelpJournal of Immunology. ePub: 13 December 2019. doi:10.4049/jimmunol.1801677

Frietze KM.*, Core SB., Linville A., Chackerian B., and DS Peabody (2020). Assessing antibody specificity in human serum using deep sequence-coupled biopanning. Methods Mol Biol 2020;2070:157-171.

Sangesland, M., Ronsard, L., Kazer, S.W., Bals, J., Boyoglu-Barnum, S., Yousif, A.S., Barnes, R., Feldman, J., Quirindongo-Crespo, M., McTamney, P.M., Rohrer, D., Lonberg, N., Chackerian, B., Graham, B.S., Kanekiyo, M., Shalek, A.K., and D. Lingwood (2019). Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. Immunity. 2019 Sep 20 Doi:

Maphis, N., Peabody, J.*, Crossey, E.*, Jiang, S., Ahmad, F., Alvarez, M., Monsoor, S.K., Yaney, A., Yang, Y. Sillerud, L., Wilson, C., Selwyn, R., Brigman, J., Cannon, J., Peabody, D.S., Chackerian, B., and K. Bhaskar (2019)Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathynpj Vaccines 4, Article number: 26. 03 June 2019

Janitzek, C.M., Peabody, J.*, Thrane, S., Carlsen, P.H.R., Theander, T.G., Salanti, A., Chackerian, B., Nielsen, M.A., and A.F. Sander (2019). A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Scientific Reports. 2019 Mar 27; 9(1): 5260. 

Kunda, N.K., Peabody, J.*, Zhai, L., Price, D.N., Chackerian, B., Tumban, E.*, and P. Muttil (2019).  Evaluation of the thermal stability and the protective efficacy of liquid and spray-dried HPV vaccine, Gardasil 9. B.  2019 Mar 18. doi: 10.1080/21645515.2019.1593727.

Frietze, KM*, Lijek, R, and B Chackerian (2018).  Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis. Expert Reviews in Vaccines.  2018 Oct 9:1-8. doi: 10.1080/14760584.2018.1534587

Ntumngia FB, Thomson-Luque R, Galusic S, Frato G, Frischmann S, Peabody DS, Chackerian B, Ferreira MU, King CL, Adams JH (2018). Identification and immunological characterization of the ligand domain of Plasmodium vivax reticulocyte binding protein 1a. Journal of Infectious Diseases. 2018 May 7. doi: 10.1093/infdis/jiy273.

Zhai L, Peabody J*, Pang YS, Schiller J, Chackerian B, and E. Tumban* (2017). A novel candidate MS2 phage VLP vaccine displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Research 2017 Sep 19. pii: S0166-3542(17)30516-8.

Peabody, J.*, Muttil, P., Chackerian, B., and E. Tumban* (2017). Characterization of a Spray-dried HPV L2-VLP Stored for Multiple Years at Room TemperaturePapillomavirus Research. June 2017; 3: 116-120.

Frietze, K.*, Pascale, J.M., Moreno, B., Chackerian, B., and D.S. Peabody (2017)Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses. PLoS One 2017 Feb 2;12(2):e0171511. doi: 10.1371/journal.pone.0171511.

Daly, S.M., Joyner, J.A., Triplett, K.D., Elmore, B.O., Pokhrel, S., Frietze, K.M., Peabody, D.S., Chackerian, B., and P.R. Hall (2017)VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulationScientific Reports 7, Article number 637 (2017).

Chackerian, B.* and A.T. Remaley (2016). Vaccine strategies for lowering LDL by immunization against PCSK9. Current Opinion in Lipidology. 2016 Aug;27(4):345-50.

Saboo, S., Tumban, E.*, Peabody, J.*, Wafula, D., Peabody, D.S., Chackerian, B., and P. Muttil (2016).  An optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus. Molecular Pharmaceutics. 2016 May 2;13(5):1646-55.

Frietze, K.M.*, Roden, R.B.S., Lee, J-H., Shi, Y., Peabody, D.S., and B. Chackerian* (2016). Identification of anti-CA125 antibody responses in ovarian cancer patients by a novel deep sequence-couple biopanning platform. Cancer Immunology Research. 2016 Feb;4(2):157-64.

Frietze, K.M.*, Peabody, D.S., and B. Chackerian* (2016).  Engineering virus-like particles as vaccine platforms. Current Opinion in Virology. 2016 Jun 18: 44-49.

Chackerian, B.* and K.M. Frietze* (2016). Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Review of Vaccines. 2016 Feb 26. [Epub ahead of print]

Jiang, R.T., Schellenbacher, C., Chackerian, B., and R.B.S. Roden (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Review of Vaccines. 2016 Mar 10:1-10.

Caldeira, J., Bustos, J., Peabody, J.*, Chackerian, B., and D. S. Peabody (2015). A Contraceptive Vaccine on a Virus-like Particle Platform. PLoS One. 2015 Oct 30;10(10):e0141407.

Crossey, E.*, Amar, M.J.A., Sampson, M., Peabody, J.*, Schiller, J.T., Chackerian, B.*, and A.T. Remaley (2015). A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine. 2015 Oct 26;33(43):5747-55. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26

Crossey, E.*, Frietze, K., Narum, D. L., Peabody, D. S., and B. Chackerian* (2015)Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide DisplayPLoS One. 2015 Jul 6;10(7):e0132560.

Tumban, E.*, Muttil, P., Escobar, C. A. A., Peabody, J.*, Wafula, D., Peabody, D. S., and B. Chackerian* (2015). Preclinical Refinements of a Broadly Protective VLP-based HPV Vaccine Targeting the Minor Capsid Protein, L2. Vaccine. Jun 26;33(29):3346-53. Epub 2015 May 21.

O’Rourke, J.*, Peabody, D.S., and B. Chackerian* (2015). Affinity Selection of Epitope-based Vaccines using a Bacteriophage Virus-like Particle Platform. Current Opinion in Virology. 2015 Mar 26;11:76-82.

O’Rourke, J. P.*, Daly, S. M., Peabody, D. S., Chackerian, B., and P. R. Hall (2014)Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing PathwayPLoS One. 2014 Nov 7;9(11):e111198.

Ord, R. L., Caldeira, J. C., Rodriguez, M., Noe, A., Chackerian, B., Peabody, D. S., Gutierrez, G., and C. A. Lobo (2014). A Malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malaria Journal. 2014 Aug 18;13(1):326. [Epub ahead of print]

Tyler, M.*, Tumban, E.*, Dziduszko, A, Ozbun, M. A., Peabody, D. S., and B. Chackerian* (2014). Immunization with a consensus epitope from Human Papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.

Schiller, J.T. and B. Chackerian (2014)Why HIV Virions Have Low Numbers of Envelope Spikes; Implications for Vaccine DevelopmentPLoS Pathogens. August 7, 2014.  DOI: 10.1371/journal.ppat.1004254.

Tyler, M.*, Tumban, E.*, Peabody, D. S., and B. Chackerian* (2014). The use of hybrid Virus-like Particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnology and Bioengineering. 2014 Jun 11. doi: 10.1002/bit.25311. [Epub ahead of print].

Van Rompay, K.K.A., Hunter, Z.*, Jayashankar, K., Peabody, J.*, Montefiori, D., LaBranche, C.C., Keele, B.F., Jensen, K., Abel, K., and B. Chackerian* (2014). A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with SIVmac251. Journal of Virology. Feb;88(4):2011-24. Epub 2013 Dec 4.

McCarthy, D.P., Hunter, Z.N.*, Chackerian, B., Shea, L.D., and Miller, S.D. (2014). Targeted immunomodulation using antigen-conjugated nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. Epub 2014 Mar 10.

Tyler, M.R.*, Tumban, E.*, and B. Chackerian* (2014). Second-Generation Prophylactic HPV Vaccines: Successes and Challenges. Expert Reviews of Vaccines. Feb;13(2):247-55. Epub 2013 Dec 18

Tumban, E.*, Peabody, J.*, Peabody, D.S., and B. Chackerian* (2013). A Universal Virus-Like Particle-based Vaccine for Human Papillomavirus: Longevity of Protection and Role of Endogenous and Exogenous Adjuvants. Vaccine Sept 23;31(41):4647-4654.  Epub 2013 Aug 9.

Tumban, E.*, Peabody, J.*, Tyler, M.R.*, Peabody, D.S., and B. Chackerian* (2012). VLPs Displaying a Single L2 epitope Induce Broadly Cross-neutralizing Antibodies Against Human Papillomavirus. PLoS One 7(11): e49751. doi:10.1371/journal.pone.0049751

Cuburu, N. and B. Chackerian (2011).  Genital Delivery of Virus-like Particle and Pseudovirus Based Vaccines. Expert Reviews of Vaccines 10(9), 1245-48.

Tumban, E.*, Peabody, J.*, Peabody, D.S., and B. Chackerian (2011). A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.  PLoS One 2011; 6(8): e23310. Epub 2011 Aug 17.

Hunter, Z.*, Tumban, E.*, Dziduszko, A., and B. Chackerian (2011). Aerosol delivery of Virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine. May 5. Jun 20;29(28):4584-92. Epub 2011 May 5.

Chackerian, B., Caldeira, J. D., Peabody, J., and D. S. Peabody (2011).  Peptide Epitope Identification by Affinity Selection on Bacteriophage MS2 Virus-like Particles. Journal of Molecular Biology. Jun 3;409(2):225-37. Epub 2011 Apr 9.

B. Chackerian (2010). Virus-like Particle Vaccines for Alzheimer's Disease. Human Vaccines. 2010 Nov;6(11):926-30. Epub 2010 Nov 1.

Caldeira, J.D., Medford, A.*, Kines, R.C., Lino, C.A., Schiller, J.T., Chackerian, B., and D.S. Peabody (2010). Immunogenic Display of Diverse Peptides, Including a Broadly Cross-Type Neutralizing Human Papillomavirus L2 epitope, on Virus-like Particles of the RNA Bacteriophage PP7. Vaccine, 28 (27), 4384-4393. Epub 2010 Apr 29.

Li, Q.Y. Gordon, M. N., Chackerian, B., Alamed, J., Ugen, K. E., and D. Morgan (2010).  Virus-like Peptide Vaccines Against Aß N-terminal or C-terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant. Journal of Neuroimmune Pharmacology, 5 (1), 133-42.

Hunter, Z.*, Smyth, H. D., Durfee, P.*, and B. Chackerian (2009). Induction of mucosal and systemic antibody responses by aerosol delivery and intramuscular immunization of Virus-like Particle based vaccines targeting CCR5. Vaccine, 28 (2), 403-414. Epub 2009 Oct 20.

Peabody, D. S., Manifold-Wheeler, B.*, Medford, A.*, Jordan, S. K. Caldeira, J., and B. Chackerian (2008). Immunogenic Display of Diverse Peptides on Virus-Like Particles of RNA Phage MS2. Journal of Molecular Biology, 380, 252-263.

Chackerian, B., Durfee, M. R.*, and J. T. Schiller (2008). Virus-like Display of a Neo-self Antigen Reverses B cell Anergy in a B cell Receptor Transgenic Mouse Model. Journal of Immunology, 180 (9), 5816-5825.

B. Chackerian (2007). Virus-like Particles: Flexible Platforms for Vaccine Development. Expert Reviews of Vaccines 6 (3), 381-390.

Chackerian, B., Rangel, M.*, Hunter, Z.*, and D. S. Peabody (2006). Virus and virus-like particle based immunogens for Alzheimer's disease induce antibody responses against Amyloid-Beta without concomitant T cell responses.  Vaccine 24 (37-39),  6321-6331.

Chackerian, B., Briglio, L., Albert, P. S., Lowy, D. R., and J. T. Schiller (2004).  Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic Simian/Human Immunodeficiency Virus. Journal of Virology 78 (8), 4037-4047.

Chackerian, B., Lenz, P., Lowy, D. R., and J. T. Schiller (2002).  Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. Journal of Immunology 169 (11), 6120-6126.

Chackerian, B., Lowy, D. R., and J. T. Schiller (2001). Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. Journal of Clinical Investigation 108 (3), 415-423.

Chackerian, B., Lowy, D. R., and J. T. Schiller (1999). Induction of auto-antibodies to mouse CCR5 with recombinant papillomavirus particles. Proceedings of the National Academy of Sciences USA 96 (5), 2373-2378.


The Chackerian laboratory is interested in vaccine development; particularly the use of virus particles as platforms for antigen display. It has long been recognized that highly dense repetitive antigens such as virus particles induce strong immune responses. However, more recent studies from the Chackerian laboratory have demonstrated that antigens that are normally poorly immunogenic can be made highly immunogenic by displaying them in a multivalent, repetitive format on the surface of virus particles; essentially using viruses as scaffolds to produce novel vaccines.

This ability to enhance immunogenicity does not only apply to epitopes derived from traditional targets, such as pathogens, but also to self-antigens which are normally subject to the mechanisms of B cell tolerance. Using virus-like particles derived from RNA bacteriophage, the Chackerian lab has collaborated with David Peabody to develop a variety of tools for vaccine production and to implement a system that allows vaccines to be rapidly identified by affinity selection.

The laboratory has projects to develop novel vaccines targeting Human Papillomavirus (HPV), Neisseria gonorrhoeae (in collaboration with Ann Jerse and the Gonorrhea Vaccine Cooperative Research Center), Chlamydia (in collaboration with Kathryn Frietze), Malaria (in collaboration with Fidel Zavala and Nik Petrovsky), HIV (in collaboration with Daniel Lingwood and Moriya Tsuji), Influenza (in collaboration with Daniel Lingwood), Zika virus, Staphylococcus (in collaboration with Pam Hall), Alzheimer's Disease (in collaboration with Kiran Bhaskar), and high cholesterol (in collaboration with Alan Remaley). To learn more about our work, follow us on Twitter.

Group photo.
Chackerian Lab (October 2019)

Lab Alumni:

  • Dr. Zoe Hunter (PhD student), Senior Manager, Publications at Pharmacyclics, an AbbVie company
  • Marisa Rangel Durfee (Research Technician), Grants Program Manager at Circumvent Pharamaceuticals
  • Dr. Brett Manifold-Wheeler (Research Technician), Post-doctoral fellow, UNM Cancer Center
  • Dr. Paul Durfee (Research Technician), Research Scientist at Janssen Inc.
  • Alex Medford (MS student), Scientist, Colorado Department of Health
  • Dr. John O'Rourke (Research Assistant Professor), Head of Product Development, IntelliCyt Corporation
  • Dr. Jayne Christen (Post-doctoral fellow), Product Manager, Leidos, Inc.
  • Dr. Mitchell Tyler (PhD student), Senior Scientist, Applied Research Associates
  • Dr. Erin Crossey (MD/PhD student), Pulmonary Fellowship Program, Boston University
  • Dr. Ebenezer Tumban (Post-doctoral fellow/Research scientist), Associate Professor, Texas Tech University (Amarillo)
  • Dr. Kathryn Frietze (Post-doctoral fellow/Research Assistant Professor), Assistant Professor, UNM School of Medicine
  • Susan Core (Sr Research Specialist), Research Specialist, Frietze Laboratory, UNM
  • Dr. Naomi Lee (Post-doctoral fellow), Assistant Professor, Northern Arizona University